In this series of videos, Dr Ilan Melnick, Chief Medical Officer at Passageway Residences of Miami-Dade County, describes Abilify Asimtufii and how to introduce it in your practice. Dr Melnick discusses a wide range of topics including an overview of the evidence in schizophrenia and the benefits for patients as well as practical considerations such as which patients may be suitable and how to transition.
Abilify Asimtufii PBS Information: Authority required (STREAMLINED) Code: 16456 for Schizophrenia. This product is not listed on the PBS for the treatment of Bipolar I disorder
Please review Approved Product Information before prescribing. Product Information is available here or by calling Lundbeck on 1300 721 277
Abilify Asimtufii® is a registered trademark of Otsuka Pharmaceutical Co., Ltd. Level 2/9 Help St, Chatswood NSW 2067, Abilify Asimtufii® is co-commercialised by Lundbeck Australia Pty Ltd and Otsuka Australia Pharmaceutical Pty Ltd.
.
